Expert Perspectives on 3D Biology
We believe in the revolutionary promise of 3D biology, where organoids accurately predict real-world patient responses to novel treatments, offering:
- Less animal testing
- Safer clinical trials
- And ultimately, radically improved human health
In this piece, we’ve curated insights from our in-house experts on the role 3D biology plays in making next-gen drug discovery a reality.
Read more from 3D biology thought leaders like:
- Shantanu Dhamija, Vice President of Strategy and Innovation
- Oksana Sirenko, Ph.D., Senior Manager of Assay Development
- Victoria Marsh Durban, Ph.D., Director of Custom Organoid Services
- Nikki Carter, Director of Commercial Organoid Innovation
- Angeline Lim, Ph.D., Senior Applications Scientist
- Misha Bashkurov, Ph.D., Product Manager, Cellular Imaging
- Shawn Nielsen Alvarado, Ph.D., Drug Discovery Sales Representative
- 3D Biology: The paradigm shift in next-gen drug discovery
1. Shantanu Dhamija, Vice President of Strategy and Innovation
Shantanu Dhamija, our Vice President of Strategy and Innovation, is passionate about leveraging collaborative partnerships to drive 3D biology adoption industrywide and advocating for diversity earlier in drug development.
Check out his latest published perspectives on these topics and more:
Organoids Stand Out as Stand Ins in Drug Development | Genetic Engineering & Biotechnology News
This article explores the evolving landscape of organoid technology and its transformative impact on drug development.
New Collaboration Finds a Match Between Liver-Derived Organoids and Automated Screening Technologies | LabX
In this piece, LabX recognizes Molecular Devices as a leading force in the campaign to synergize automation with organoid development and screening.
The Benefits of AI and Automation in the Cell Culture Process | Lab Manager
In this article, we discuss the transformative role of artificial intelligence (AI) and automation in revolutionizing laboratory research, particularly in cell culture.
The importance of introducing diversity earlier in drug development | Drug Discovery World
DDW’s Reece Armstrong speaks to Shantanu Dhamija, about challenges of diversity in clinical trials and why induced pluripotent stem cells might be key to representing wider patient groups
2. Oksana Sirenko, Ph.D., Senior Manager of Assay Development
Oksana Sirenko, Ph.D., our Senior Manager of Assay Development, has loads of expertise working with complex cell-based models for 3D biology and optimizing their use with automated, AI-enabled technologies.
Check out her latest published perspectives on these topics and more:
Enhancing 3D Cell Culture Imaging | Biocompare
Here we will explore common obstacles in 3D cell culture imaging, and show you how to best visualize your samples, whether fixed or alive.
3D Imaging of Organoid Cultures | Biocompare
In this piece, Oksana shares insights on how researchers are leveraging more advanced technologies such as automated high-content imaging platforms to better capture the depth of information offered by organoid cultures.
Selecting the Right Cell-Based Assay | Biocompare
In this guide to choosing the best cell-based assays, Oksana weighs in on assay importance and their trend toward increased complexity when using 3D models.
Gene Editing In Organoids: Accounting For Complexity In Drug Discovery | Drug Discovery World
In this article, Oksana explains how gene editing to build disease models that better represent the complex biology of human tissues has the potential to improve drug discovery.
3. Victoria Marsh Durban, Ph.D., Director of Custom Organoid Services
Vicky Marsh Durban, Ph. D., our Director of Custom Organoid Services, is committed to helping researchers access large batches of standardized, assay-ready organoids for high-throughput screening, made using our patent-pending bioprocess technology.
Check out her latest published perspectives on these topics and more:
Organoids Evolve from Academic Marvel to Industrial Tool | Genetic Engineering & Biotechnology News
This article explores the growing landscape of organoid technology and its transformative impact on healthcare research and drug development.
A Decade of Transformation: How Organoids are Redefining Drug Development | Labcompare
In this Labcompare article, Vicky Marsh Durban, Director of Custom Organoid Services discusses the transformative impact of organoids in biopharma over the past decade.
Organoid Industrialization | Genetic Engineering & Biotechnology News
This article explores the industrialization of organoids for advanced drug discovery. Inside, Vicky speaks about Molecular Devices' custom organoid expansion service, using proprietary bioreactor and bioprocessing technology to produce millions of organoids.
Improving Drug Development: Molecular Devices and Cellesce Aim to Advance the Use of Organoids | Instrument Business Outlook
Molecular Devices and Cellesce aim to advance the use of organoids technologies, which it views as the future of drug discovery and development.
4. Nikki Carter, Director of Commercial Organoid Innovation
Nikki Carter, our Director of Commercial Organoid Innovation, leverages decades of experience in large pharmaceutical companies to help researchers optimize organoid-based drug discovery and high-throughput screening programs.
Check out her latest published perspectives on these topics and more:
A Three-Pillar Approach to Driving Organoid Adoption in Drug Discovery | Biocompare
In this article, we discuss how a comprehensive three-pillar strategy could bolster organoid scalability, reproducibility, and regulatory acceptance to advance scientific discovery industrywide.
Patient-derived organoids in disease modeling | Drug Target Review
In an interview with Nikki Carter at Molecular Devices, we explore the the power of patient-derived organoids (PDOs) in drug discovery.
5. Angeline Lim, Ph.D., Senior Applications Scientist
Angeline Lim, Ph.D., our Senior Applications Scientist, specializes in high-content imaging and analysis. She works predominately in developing automated 3D biology workflows and leverages AI to derive actionable readouts from complex phenotypic assays. (Among many other, science things! Outside of the lab, she’s a pro at raising cute little chickens in her backyard for home-grown eggs. Just ask her.)
Check out her latest published perspectives:
AI Takes On Drug Discovery | Genetic Engineering & Biotechnology News
In this Genetic Engineering & Biotechnology News article, reporter Mike May takes a fresh look at how using AI for drug discovery reveals new targets and tactics for treating diseases. Molecular Devices’ Angeline Lim weighs in with ways AI-enabled image analysis software uncovers more insights while healing the pains of a traditional, manual approach.
6. Misha Bashkurov, Ph.D., Product Manager, Cellular Imaging
Misha Bashkurov, Ph.D., our Cellular Imaging Product Manager, gleans insights from customers to develop cutting-edge, data analysis software solutions that respond to current pain points, enabling an expedited R&D process for leading drug discovery researchers.
Check out his latest published perspectives:
Curing the Image Analysis Headache with Deep Learning | Technology Networks
In this article, Misha discusses how deep learning is revolutionizing the field of image analysis and addressing the challenges researchers face in optimizing analysis parameters. Traditionally, adjusting parameters for accurate image analysis has been lengthy and frustrating. Deep-learning algorithms offer a solution by learning from example images and automating the parameter-setting process, saving researchers time and effort.
7. Shawn Nielsen Alvarado, Ph.D., Drug Discovery Sales Representative
Shawn Nielsen Alvarado, Ph.D., our Drug Discovery Sales Representative, introduces prospective customers to our high-content imaging and screening systems to advance their research.
Check out her latest published perspectives:
Achieving Accurate Raw Images with High-content Screening | Labcompare
In this editorial piece, Drug Discovery Sales Representative Shawn Nielsen Alvarado discusses the transformative impact of HCS in cell-based assays, drug target discovery, functional assays, and toxicology studies.
She explores how HCS, with its end-to-end automation and advanced computational algorithms, accelerates scientific breakthroughs by providing rapid, reliable, and multiparametric analyses that push the boundaries of biomedical knowledge.
3D Biology: The paradigm shift in next-gen drug discovery
We believe organoids are the future of next-gen drug discovery, offering revolutionary promises to reduce drug development timelines, overcome limitations of conventional cell models, and move us away from animal research.
Are you ready to transition from 2D to 3D biology, but not sure where to start? In our latest blog, we show you what it takes to enter into this new drug discovery paradigm.
